Open AccessDelamanid: A new armor in combating drug-resistant tuberculosis
Author(s) -
Alphienes Stanley Xavier,
Mageshwaran Lakshmanan
Publication year - 2014
Publication title -
journal of pharmacology and pharmacotherapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.301
H-Index - 34
eISSN - 0976-5018
pISSN - 0976-500X
DOI - 10.4103/0976-500x.136121
Subject(s) - drug , medicine , drug resistance , tuberculosis , mycobacterium tuberculosis , bedaquiline , tolerability , intensive care medicine , drug resistant tuberculosis , human immunodeficiency virus (hiv) , pharmacology , virology , adverse effect , biology , microbiology and biotechnology , pathology
Intense search has been made in the discovery of newer anti-TB drugs to tackle the issues such as drug resistance, HIV co-infection and risk of drug-drug interactions in the management of TB. Delamanid, a newer mycobacterial cell wall synthesis inhibitor, received a conditional approval from European medicines agency (EMA) for the treatment of MDR-TB. Preclinical and clinical studies have shown that delamanid has high potency, least risk for drug-drug interactions and better tolerability.